A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma
Tumori Journal · 2024
DOI: 10.1177/03008916231217583 ↗Kurz gefasst
Editorial in der Zeitschrift Tumori Journal, 2024. Verfasst von Antonio Silvani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
, where it occurs in almost as much as 90% of cases regardless of grading, and in non-co-deleted IDH-mutant astrocytomas, where it affects approximately 35% of patients. Grade 4 glioblastomas and astrocytomas expressing the IDh mutation are a numerically tiny group. The INDIGO trial (NCT04164901) is a randomized, double-blind, controlled phase III trial. A total of 340 patients with mutant grade II gliomas were enrolled, including oligodendrogliomas and astrocytomas, and randomized (1:1) to receive vorasetinib or placebo. Patients were eligible if they were 12 years or older and had histologically confirmed grade 2 residual or recurrent oligodendroglioma or astrocytoma (according to WHO 2016 criteria) with centrally confirmed IDH1 and IDH2 mutation status. Other critical eligibility criteria included a Karnofsky performance status (KPS) score of at least 80, at least one previous surgery (with the most recent surgery occurring between one and five years before randomization), no other anticancer treatment for glioma, and no use of steroids for signs or symptoms of glioma. Of note, patients should be considered by investigators to be appropriate candidates for a watch-and-wait approach and not to be at high risk (with uncontrolled seizures, brainstem involvement, and clinically relevant functional or neurocognitive deficits caused by the tumor). Patients had measurable, non-enhancing disease assessed centrally and these were patients with non-enhancing
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
- IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
ORCID-Profile: Antonio Silvani
Zitieren
APA
Silvani, A., & Franceschi, E. (2024). A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma. Tumori Journal. https://doi.org/10.1177/03008916231217583
Vancouver
Silvani A, Franceschi E. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma. Tumori Journal. 2024. doi:10.1177/03008916231217583
BibTeX
@article{Silvani2024,
author = {Silvani, Antonio and Franceschi, Enrico},
title = {A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma},
journal = {Tumori Journal},
year = {2024},
doi = {10.1177/03008916231217583}
}
EUVIMED